Two drugs, lecanemab (Leqembi) and donanemab (Kisunla), address the underlying biology of the disease by removing beta-amyloid clumps from the brain. The drugs have been shown to slow the progression of cognitive decline when they’re started in early-stage Alzheimer’s. Both can cause brai...